To further validate ALK as a suitable target for the sensitization of neuroblastoma cells to HDAC8 inhibitor treatment, SK-N-BE(2)-C cells were transfected with the two most effective single ALK siRNAs and treated with the HDAC8 inhibitor PCI-34051 [14] (Fig. 4a), and vice versa, SK-N-BE(2)-C cells transfected with an siRNA pool against HDAC8 (Fig. 4b) were treated with crizotinib. The gene discussed is ALK; the disease is neuroblastoma.